Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring, Other Jul 16 | 2021GSK Releases Positive Dapro Topline Results Day After Negative Roxa Adcom; Dexcom Cleared for Third-party Integration; New Medtronic Klue Trial ObservedPurchase Blast
$599
Posted in: Other Jul 15 | 2021Roxa Adcom Votes Overwhelmingly Against Approval in NDD (1-13) and DD (2-12)Purchase Blast
$599
Posted in: Other Jul 13 | 2021Roxa Adcom Docs Released: FDA Mixed on Risk-BenefitPurchase Blast
$599
Posted in: Other, SGLT2i Jul 12 | 2021Novo Buys Cardiomyopathy Asset From Prothena; Teplizumab Receives UK Innovation Passport; Poxel Reorganizes Strategic Direction; Dario Announces New Employer Contracts; New Generic Sitagliptin Received Tentative ApprovalPurchase Blast
$599
Posted in: Glucose Monitoring Jul 07 | 2021CGM Patent-infringement Suits: Dexcom Sues Abbott; Abbott Sues DexcomPurchase Blast
$599
Posted in: Other Jul 06 | 2021Novartis Resubmits Inclisiran NDA; Provention Bio Receives CRL for TeplizumabPurchase Blast
$599
Posted in: SGLT2i Jul 06 | 2021Jardiance Positive HFpEF Topline Results (EMPEROR-Preserved)Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Jul 01 | 2021Why Lilly Will Terminate GGG; Lilly ADA 2021 Investor UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other, SGLT2i Jun 29 | 2021ADA 2021 Key Press Releases (June 29)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, SGLT2i Jun 28 | 2021ADA 2021 Key Press Releases (June 28)Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Jun 28 | 2021Novo Dual Agonist T2DM Intentions Disclosed at ADA Investor Event; Lilly Could Pursue Hypo Claim vs. Degludec in QW Basal Ph3Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 27 | 2021ADA 2021 Key Press Releases (June 27)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 25 | 2021ADA 2021 Key Press Releases (June 25)Purchase Blast
$599
Posted in: Dual/triple agonist, Glucagon, Glucose Monitoring, Insulin Delivery Jun 24 | 2021Bigfoot Unity and Zegalogue RTU Dasiglucagon Now Available in the US; Carmot Initiates GIP/GLP Trial in Obesity and T2DM; Dexcom Launches TIR Educational Campaign; Dario Selected as Digital Health Provider for Coastal Family Health CenterPurchase Blast
$599
Posted in: Other Jun 23 | 2021Imeglimin Approved in Japan as "Twymeeg"; Diamyd Q1 '21 Business UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jun 22 | 2021Bigfoot Unity Video Highlights Connected System; Celon’s Next-gen GPR40 Enters Ph2 DevelopmentPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
